Echo IQ (EIQ) H2 2026 earnings summary

Executive summary

• Achieved significant progress in commercialisation, expanding US hospital pipeline and deploying EchoSolv AS at major institutions like Mount Sinai and Beth Israel Deaconess Medical Center.

• Completed independent validation of EchoSolv HF, submitted FDA 510(k) application, and expanded Mayo Clinic partnership for potential distribution.

• Entered binding Heads of Agreement with Pro Medicus for up to A$20m investment and US reseller partnership.

• Strengthened balance sheet post-year-end with A$110m institutional placement and exclusive data-licensing agreement with Advara HeartCare.

Financial highlights

• Reported FY26 net loss of $18.6m, compared to $13.3m loss in FY25.

• Operating revenue was $91.6k, down from $101.4k in FY25.

• Operating expenses (excluding share-based payments) rose to $13.7m from $8.7m year-over-year.

• Cash and cash equivalents at 30 June 2026 were $8.7m.

• Net assets decreased to $11.6m from $22.8m at prior year-end.

Outlook and guidance

• FY27 priorities include converting US pipeline into enterprise deployments, expanding EchoSolv AS utilisation, progressing Pro Medicus partnership, and preparing for EchoSolv HF commercial launch pending FDA clearance.

• Focus on integrating Advara HeartCare dataset, advancing new cardiovascular indications, and expanding US sales and implementation capabilities.